Researchers Find New Leukemia Genes using CRISPR Technology

Apr. 20, 2020
Jeevisha Bajaj, Ph.D.

Using the most advanced tools available, scientists discovered several novel genes not known to be involved in blood cancers, and used the powerful new data to paint a clearer map for how aggressive leukemia arises and grows, according to an article published in Nature Cancer.

Jeevisha Bajaj, Ph.D., assistant professor of Biomedical Genetics at the University of Rochester Medical Center and a researcher at the Wilmot Cancer Institute, is the lead author of the study. Bajaj conducted the research while she was a project scientist in the laboratory of Tannishtha Reya Ph.D., professor of Pharmacology and Medicine at the University of California, San Diego School of Medicine, and senior author of the study.

The paper points to several significant discoveries:


  • It unveiled a new gene, Staufen 2 (Stau2), that regulates and drives the molecular programs for leukemia stem cells, the cells responsible for propagating the disease and for therapy resistance. Stau2 has been previously studied in the brain and nervous system but until now was not known to have a role in cancer.
  • The team used a tool known as CRISPR, which allows scientists to edit DNA in cells and focus on large groups of genes active in a particular disease - in this case, myeloid leukemias. The paper showed that CRISPR can identify an entire class of gene mediators for leukemia, which will aid future research.
  • The team also tested its hypothesis in a mouse model designed to mimic the human experience with leukemia, as opposed to conducting studies solely in cell cultures, as several other groups had previously done.

Leukemia research is important because the survival rate is less than 10 percent for the most aggressive forms of the disease. In this case, investigators focused on chronic myeloid leukemia (CML), which can be well-controlled with targeted therapies such as Gleevec. But CML is lethal when it advances or is diagnosed in an acute “blast” phase. The findings also have implications for acute myeloid leukemia (AML) and other blood cancers.

“This work will be particularly important for the discovery of new treatments," Bajaj said. “Our genome-wide screen identified cellular signals critical for the growth of cancer, and in the future, this study will be useful to study the microenvironment, the area around the tumor that includes tissue, blood vessels and important molecular signals related to how the cancer behaves."

Bajaj joined Wilmot in November of 2019, after building a career at UC San Diego as a cancer and stem-cell biologist.

Before the team identified Stau2 and its essential function in leukemia, they discovered a broader group of RNA-binding proteins (RBPs), a family of genes that have recently started to be of interest in leukemia. The authors focused on a subset that had not been studied previously in any cancer, and found six of these RBPs to be abundantly expressed in human leukemia stem cells. After further investigation of RBPs, Stau2 emerged as a critical regulator of the growth of CML in the blast phase, and AML.

Furthermore, researchers were able to delete Stau2 in laboratory experiments and show they could block the growth of cancer cells. The next step is to identify how to target Stau2 and other related genes for the benefit of patients.

Bajaj was supported by a scholar award from the American Society of Hematology and a postdoctoral fellowship from the National Cancer Center; the research was also supported by several National Institutes of Health grants to Reya.